NervGen Pharma Corp.

Recent News

  • NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer

    Vancouver, British Columbia--(Newsfile Corp. - November 27, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. Paul Brennan to the position of President & CEO ...

    2019-11-27 8:00 AM ET
  • NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio

    Vancouver, British Columbia--(Newsfile Corp. - November 21, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that, further to its press release dated November 18, 2019, it has ...

    2019-11-21 8:30 AM ET
  • NervGen Pharma Receives Investment from Drug Manufacturing Partner

    Vancouver, British Columbia--(Newsfile Corp. - November 18, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced that it has entered into an agreement to issue 1,500,000 common shares ...

    2019-11-18 8:30 AM ET
  • NervGen Pharma Expands Platform into Alzheimer's Disease

    Vancouver, British Columbia--(Newsfile Corp. - October 28, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating novel treatments for nerve damage and neurodegenerative diseases, today announced a research initiative to advance its proprietary therapeutic technology platform, currently in development ...

    2019-10-28 7:30 AM ET
  • NervGen Pharma Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases

    Vancouver, British Columbia--(Newsfile Corp. - September 6, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the clinical development strategy for its compound, NVG-291, in two ...

    2019-09-06 7:30 AM ET
  • NervGen Pharma's Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper

    Vancouver, British Columbia--(Newsfile Corp. - July 10, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reports the publication of a new, independent study using NervGen's ...

    2019-07-10 8:00 AM ET
  • NervGen Amends Investor Relations Agreement

    Vancouver, British Columbia--(Newsfile Corp. - July 5, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the Company has agreed to amend the terms of ...

    2019-07-05 4:00 PM ET
  • NervGen Pharma Launches Multiple Sclerosis Program Targeting Nerve Remyelination

    Vancouver, British Columbia--(Newsfile Corp. - June 26, 2019) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced its goal to apply its proprietary platform drug technology beyond ...

    2019-06-26 8:00 AM ET